The trial marks the first time the drug has been tested for treating nasal conditions. Nasal polyps are thought to affect ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...